AllStripes Announces $50 Million Series B Financing to Advance Global Rare Disease Research - BusinessWire
AllStripes Announces Collaboration with NIH’s NCATS to Launch Effort in Rare Disease Diagnosis - BusinessWire
AllStripes Awarded as Technology Pioneer by World Economic Forum - BusinessWire
AllStripes is a healthcare technology company that accelerates drug development and research for the treatment of rare diseases.
AllStripes’ mission is to unlock new treatments for people with rare diseases. As the first and only research platform dedicated to rare diseases, AllStripes makes it easy for patients to contribute to new treatment studies from home. Medical data science that empowers patients and communities to generate regulatory-ready evidence for drug research in rare diseases.
AllStripes aggregates and analyzes medical records and sells the de-identified data to pharmaceutical companies to help them develop medicines. In exchange for access to the data, patients gets their fragmented medical records organized into an app they can use to track their treatment and get second opinions.
AllStripes is privately funded by Spark Capital, Lux Capital, Maveron, and Village Global, a venture capital firm with a network of LPs including Reid Hoffman, Bill Gates, Mark Zuckerberg, and Jeff Bezos.
ClientAllstripesLinkAllstripes.com